OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report)'s share price dropped 13.7% during trading on Tuesday . The stock traded as low as $2.13 and last traded at $2.21. Approximately 201,376 shares traded hands during trading, an increase of 41% from the average daily volume of 143,002 shares. The stock had previously closed at $2.56.
Wall Street Analyst Weigh In
Separately, HC Wainwright restated a "buy" rating and set a $7.00 price target on shares of OKYO Pharma in a research note on Monday, May 5th.
Get Our Latest Stock Analysis on OKYO Pharma
OKYO Pharma Stock Down 13.7%
The business's 50 day moving average is $1.64 and its two-hundred day moving average is $1.33.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in OKYO Pharma stock. Dauntless Investment Group LLC acquired a new stake in OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Free Report) in the first quarter, according to its most recent filing with the SEC. The fund acquired 1,988,780 shares of the company's stock, valued at approximately $2,526,000. OKYO Pharma makes up 3.0% of Dauntless Investment Group LLC's holdings, making the stock its 2nd largest holding. Dauntless Investment Group LLC owned approximately 5.88% of OKYO Pharma as of its most recent filing with the SEC. 2.97% of the stock is owned by institutional investors.
OKYO Pharma Company Profile
(
Get Free Report)
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider OKYO Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OKYO Pharma wasn't on the list.
While OKYO Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
